#136289
Re: Farmas USA
PFE
Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance
- Full-Year 2025 Revenue Guidance(1) Range of $61.0 to $64.0 Billion
- Full-Year 2025 Adjusted(2) Diluted EPS Guidance Range of $2.80 to $3.00
- Expect Full-Year 2025 Adjusted(2) Diluted EPS Operational(3) Growth of 10% to 18% from the Midpoint of 2024 Guidance After Adjusting for 2024 Non-Recurring Items(4)
- Achieved Goal of $4.0 Billion in Net Cost Savings Through 2024 and Anticipate an Additional $500 Million in Savings in 2025 from Ongoing Cost Realignment Program
- First Phase of Manufacturing Optimization Program On Track to Deliver Initial Net Cost Savings in the Latter Part of 2025, Toward Goal of Improving Gross Margin Performance
Trimestral de 25 años
